Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449681 | 1.00 | POLB (0.43) | POLBCYP1A2CYP2A6TSHRKDM4E | |
| Hydrochloric Acid SCHEMBL809034 | 0.86 | KDM4E (0.43) | CYP1A2CYP2A6TSHRKDM4EALDH1A1 | |
| SCHEMBL809176 | 0.80 | CTSD (0.49) | POLBCYP1A2KDM4EALDH1A1HPGD | |
| SCHEMBL6374171 | 0.80 | TSHR (0.48) | POLBCYP1A2CYP2A6TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL9314547 | 0.78 | ACP3 (0.42) | POLBCYP1A2CYP2A6TSHRGAA | |
| SCHEMBL809162 | 0.78 | L3MBTL1 (0.49) | POLBTSHRKDM4EALDH1A1HPGD | |
| SCHEMBL11585864 | 0.78 | TSHR (0.50) | CYP1A2CYP2A6TSHRKDM4EALDH1A1 | |
| SCHEMBL2582559 | 0.77 | PTGS2 (0.49) | POLBCYP1A2ALDH1A1GAAMEN1 | |
| SCHEMBL6244670 | 0.77 | NR1H4 (0.52) | POLBALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL18415509 | 0.76 | TSHR (0.48) | POLBCYP1A2CYP2A6TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589171-B2 | 177-Lu labeled peptide for site-specific uPAR-targeting | TRT INNOVATIONS APS (DK) | 2026-03-31 | — | — | US | claimed |
| EP-4448020-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT AS (DK) | 2026-02-04 | — | — | EP | claimed |
| EP-4678194-A1 | THERAPEUTIC APPLICATION OF 64CU-LABELLED CONJUGATES FOR SITE-SPECIFIC UPAR-TARGETING | Curasight A/S (DK) | 2026-01-14 | — | — | EP | claimed |
| EP-4651912-A1 | RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING | Curasight A/S (DK) | 2025-11-26 | — | — | EP | claimed |
| US-20250319215-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | CURASIGHT AS (DK) | 2025-10-16 | — | — | US | claimed |
| US-12409240-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | CURASIGHT A/S (DK) | 2025-09-09 | — | — | US | claimed |
| US-20250049971-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT A/S (DK) | 2025-02-13 | — | — | US | claimed |
| WO-2024153756-A1 | RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING | CURASIGHT A/S (DK) | 2024-07-25 | — | — | WO | claimed |
| EP-3590542-B1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | CURASIGHT AS (DK) | 2024-01-03 | — | — | EP | claimed |
| EP-4197561-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | Curasight A/S (DK) | 2023-06-21 | — | — | EP | claimed |
| US-20220202966-A1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | CURASIGHT A/S (DK) | 2022-06-30 | — | — | US | claimed |
| US-11311637-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | CURASIGHT A/S (DK) | 2022-04-26 | — | — | US | claimed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | claimed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | claimed |
| US-12589171-B2 | 177-Lu labeled peptide for site-specific uPAR-targeting | TRT INNOVATIONS APS (DK) | 2026-03-31 | — | — | US | disclosed |
| EP-4448020-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT AS (DK) | 2026-02-04 | — | — | EP | disclosed |
| EP-4678194-A1 | THERAPEUTIC APPLICATION OF 64CU-LABELLED CONJUGATES FOR SITE-SPECIFIC UPAR-TARGETING | Curasight A/S (DK) | 2026-01-14 | — | — | EP | disclosed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | disclosed |
| EP-1593674-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589171-B2 | 177-Lu labeled peptide for site-specific uPAR-targeting | LNPEP, XPNPEP2, PLAUR | POLB 1573/4885CYP1A2 4706/4885CYP2A6 4658/4885 |
| US-20220202966-A1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | PLAUR, PLAU, SERPINE1 | POLB 1962/4885CYP1A2 4847/4885CYP2A6 4841/4885 |
| US-12409240-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | PLAUR, PLAU, SERPINE1 | POLB 1962/4885CYP1A2 4847/4885CYP2A6 4841/4885 |
| US-11311637-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | PLAUR, PLAU, SERPINE1 | POLB 1962/4885CYP1A2 4847/4885CYP2A6 4841/4885 |
| US-20250049971-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | PLAUR, PLAU, PROKR1 | POLB 1298/4885CYP1A2 4861/4885CYP2A6 4792/4885 |
| US-20250319215-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | PLAUR, PLAU, SERPINE1 | POLB 1629/4885CYP1A2 4846/4885CYP2A6 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.